Table 1:
Clinical and pathological characteristics of study population
| Parameter | Category | Frequency | % |
|---|---|---|---|
| Age (years) | |||
| <50 | 57 | 28.2 | |
| ≥50 | 145 | 71.8 | |
| ER status (n=201) | |||
| Positive | 116 | 57.7 | |
| Negative | 85 | 42.3 | |
| PR status | |||
| Positive | 90 | 47.1 | |
| Negative | 101 | 52.9 | |
| HER2 status | |||
| Positive | 28 | 13.9 | |
| Negative | 173 | 86.1 | |
| Subtype* | |||
| Luminal A | 88 | 43.8 | |
| Luminal B | 29 | 14.4 | |
| Her2 | 17 | 8.5 | |
| Triple-negative | 67 | 33.3 | |
| Pathologic stage (n=197) | |||
| Stage 1 | 62 | 31.5 | |
| Stage 2 | 82 | 41.6 | |
| Stage 3 | 41 | 20.8 | |
| Stage 4 | 12 | 6.1 | |
| Grade | |||
| Grade I | 9 | 4.5 | |
| Grade II | 57 | 28.2 | |
| Grade III | 136 | 67.3 | |
| Recurrence | |||
| None | 136 | 67.3 | |
| Loco-regional | 11 | 5.4 | |
| Distant | 21 | 10.4 | |
| Never disease-free | 18 | 8.9 | |
| Unknown | 16 | 7.9 | |
ER: estrogen receptor; PR: progesterone receptor; HER2: Human Epidermal Growth Factor Receptor 2, Luminal A: ER+ or PR+, HER2-; luminal B: ER+ or PR+, HER2+; triple-negative: ER-, PR-, HER2-; HER2+: ER-, PR-, HER2+